Linkage of Molecular and Epidemiological Breast Cancer Investigations with Treatment Data: A Specialized Registry

1998 ◽  
Author(s):  
O. R. McIntyre
Keyword(s):  
Breast Cancer ◽  
Treatment Data

scholarly journals A pan-Canadian prospective study of young women with breast cancer: the rationale and protocol design for the RUBY study

2020 ◽  
Vol 27 (5) ◽  
Author(s):  
M.L. Quan ◽  
I.A. Olivotto ◽  
N.N. Baxter ◽  
C.M. Friedenreich ◽  
K. Metcalfe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Treatment Quality ◽  
Future Research ◽  
Delivery Of Care ◽  
Younger Women ◽  
Core Dataset ◽  
Patient Reported ◽  
Treatment Data

Introduction The understanding of the biology and epidemiology of, and the optimal therapeutic strategies for, breast cancer (bca) in younger women is limited. We present the rationale, design, and initial recruitment of Reducing the Burden of Breast Cancer in Young Women (ruby), a unique national prospective cohort study designed to examine the diagnosis, treatment, quality of life, and outcomes from the time of diagnosis for young women with bca. Methods Over a 4-year period at 33 sites across Canada, the ruby study will use a local and virtual recruitment model to enrol 1200 women with bca who are 40 years of age or younger at the time of diagnosis, before initiation of any treatment. At a minimum, comprehensive patient, tumour, and treatment data will be collected to evaluate recurrence and survival. Patients may opt to complete patient-reported questionnaires, to provide blood and tumour samples, and to be contacted for future research, forming the core dataset from which 4 subprojects evaluating genetics, lifestyle factors, fertility, and local management or delivery of care will be performed. Summary The ruby study will be the most comprehensive repository of data, biospecimens, and patient-reported outcomes ever collected with respect to young women with bca from the time of diagnosis, enabling research unique to that population now and into the future. This research model could be used for other oncology settings in Canada.

Bevacizumab plus chemotherapy in the treatment of metastatic breast cancer: Hospital of Cruces experience.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11525-e11525 ◽  
Author(s):  
Josefa Ferreiro ◽  
Abigail Ruiz de Lobera ◽  
Aintzane Sancho ◽  
Sergio Carrera ◽  
Ines Marrodan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Maintenance Therapy ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Retrospective Chart Review ◽  
Progression Free Survival ◽  
Cytotoxic Agents ◽  
Treatment Data ◽  
Ecog Ps

e11525 Background: Antiangiogenic therapies such as bevacizumab (BV), have proven to be effective in improving outcomes in metastatic disease from several tumor types. For metastatic breast cancer (MBC), combinations of BV and established chemotherapy regimens potentially offer new, more efficacious treatments without the significant toxicity associated with combining multiple cytotoxic agents. Methods: This is a retrospective chart review that reflects Hospital of Cruces experience with BV in combination with chemotherapy in patients with MBC. Demographic and treatment data were collected from diagnosis and follow-up period. Results: A total of 66 patients were included. Median age was 53(34-78) years. ECOG PS 0/1/2/3 was 35%/51.5%/10.5%/3%, respectively. Positive hormone receptor (66.7%) and negative hormone receptor (33.3%). Her2 negative and triple negative were 100% and 33.3% of the patients. Adjuvant treatment received was 81.8% chemotherapy and 56.1% hormone therapy. Most frequent metastasis locations: bone (68%), liver 54.5%, lymph nodes (51.5%) and lung (27.3%). Thirty-five patients reported two or 3 metastasis locations. Chemotherapy used with BV was docetaxel (68.2%) and paclitaxel (31.8%). Median of BV courses was 6 (1-20). Response rate was 57.5% (53% partial response) and 28.8% had stable disease. Median Progression Free Survival (PFS) was 11.7 months and median OS was 19.7 months. Statistical differences were observed between patients who received a maintenance therapy with BV vs patients who received no maintenance therapy (PFS: 9.34 vs 15.36 months, p<0.001; OS: 13.81 vs 25.56 months, p<0.001). Most frequent toxicities 3/4 were: neutropenia 31.8%, febrile neutropenia 21.2%, asthenia 21.2%, infection 9.1% and onycholysis 6.1%. Conclusions: BV in combination with chemotherapy improves clinical benefit in terms of increased PFS and OS in first-line treatment of metastatic breast cancer. Maintenance with BV revealed statistical differences. Toxicity profile was manageable and as expected for BV.

Follow-up care of breast cancer survivors: Survey of patients and analysis of treatment data in a German breast cancer centre.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20602-e20602
Author(s):  
Stefan Feiten ◽  
Jan Dünnebacke ◽  
Vera Friesenhahn ◽  
Jochen Heymanns ◽  
Hubert Koeppler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Cancer Centre ◽  
Follow Up Care ◽  
Treatment Data

scholarly journals Reliability of Self-reported Treatment Data by Patients With Breast Cancer Compared With Medical Record Data

2018 ◽  
Vol 18 (3) ◽  
pp. 234-238 ◽  
Author(s):  
Melissa Kool ◽  
Esther Bastiaannet ◽  
Cornelis J.H. Van de Velde ◽  
Perla J. Marang-van de Mheen
Keyword(s):  
Breast Cancer ◽  
Medical Record ◽  
Medical Record Data ◽  
Record Data ◽  
Treatment Data

scholarly journals Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database

2014 ◽  
Vol 32 (19) ◽  
pp. 2018-2024 ◽  
Author(s):  
Natasha M. Rueth ◽  
Heather Y. Lin ◽  
Isabelle Bedrosian ◽  
Simona F. Shaitelman ◽  
Naoto T. Ueno ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Survival Rates ◽  
National Cancer Data Base ◽  
Significant Independent Predictor ◽  
Trimodality Therapy ◽  
Cancer Data ◽  
Treatment Data ◽  
Trimodality Treatment ◽  
The Impact

Purpose To analyze factors that predict the use of trimodality treatment (chemotherapy, surgery, and radiation therapy [RT]) and evaluate the impact that trimodality treatment use has on survival for patients with inflammatory breast cancer (IBC). Methods Using the National Cancer Data Base, patients who underwent surgical treatment of nonmetastatic IBC from 1998 to 2010 were identified. We collected demographic, tumor, and treatment data and analyzed treatment and survival trends over time. Logistic regression and Cox proportional hazard models were used to examine factors predicting treatment and survival. Results We identified 10,197 patients who fulfilled study criteria. The use of trimodality therapy fluctuated annually (58.4% to 73.4%). Patients who were older, diagnosed earlier in the study period, lived in regions of the country outside of the Midwest, had lower incomes or public insurance, and had a higher comorbid score were significantly less likely to receive trimodality therapy (all P < .05). Five- and 10-year survival rates were highest among patients receiving trimodality treatment (55.4% and 37.3%, respectively) compared with patients who received the combination of surgery plus chemotherapy, surgery plus RT, or surgery alone. After adjusting for potential confounding variables, use of trimodality therapy remained a significant independent predictor of survival. Conclusion Underutilization of trimodality therapy negatively impacted survival for patients with IBC. The use of trimodality therapy increased marginally with time, but there remain significant factors associated with differences in use of trimodality treatment. We have identified specific barriers to care that may be targeted to improve treatment delivery and potentially improve patient outcomes.

scholarly journals Validity of Administrative Databases in Comparison to Medical Charts for Breast Cancer Treatment Data

2018 ◽  
Vol 2018 ◽  
pp. 1-12
Author(s):  
Ashini Weerasinghe ◽  
Courtney R. Smith ◽  
Vicky Majpruz ◽  
Anjali Pandya ◽  
Kristina M. Blackmore ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Administrative Data ◽  
Screening Program ◽  
Breast Cancer Treatment ◽  
Activity Level ◽  
Administrative Databases ◽  
Partial Mastectomy ◽  
Trend Test ◽  
Treatment Data

Objective. Medical chart abstraction is the gold standard for collecting breast cancer treatment data for monitoring and research. A less costly alternative is the use of administrative databases. This study will evaluate administrative data in comparison to medical charts for breast cancer treatment information. Study Design and Setting. A retrospective cohort design identified 2,401 women in the Ontario Breast Screening Program diagnosed with invasive breast cancer from 2006 to 2009. Treatment data were obtained from the Activity Level Reporting and Canadian Institute of Health Information databases. Medical charts were abstracted at cancer centres. Sensitivity, specificity, positive and negative predictive value, and kappa were calculated for receipt and type of treatment, and agreement was assessed for dates. Logistic regression evaluated factors influencing agreement. Results. Sensitivity and specificity for receipt of radiotherapy (92.0%, 99.3%), chemotherapy (77.7%, 99.2%), and surgery (95.8%, 100%) were high but decreased slightly for specific radiotherapy anatomic locations, chemotherapy protocols, and surgeries. Agreement increased by radiotherapy year (trend test, p<0.0001). Stage II/III compared to stage I cancer decreased odds of agreement for chemotherapy (OR = 0.66, 95% CI: 0.48–0.91) and increased agreement for partial mastectomy (OR = 3.36, 95% CI: 2.27–4.99). Exact agreement in treatment dates varied from 83.0% to 96.5%. Conclusion. Administrative data can be accurately utilized for future breast cancer treatment studies.

Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

2005 ◽  
Vol 23 (12) ◽  
pp. 2716-2725 ◽  
Author(s):  
Ivo A. Olivotto ◽  
Chris D. Bajdik ◽  
Peter M. Ravdin ◽  
Caroline H. Speers ◽  
Andrew J. Coldman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
British Columbia ◽  
Prognostic Factors ◽  
Systemic Therapy ◽  
Population Based ◽  
Adjuvant Systemic Therapy ◽  
Cancer Outcomes ◽  
Cancer Specific Survival ◽  
Breast Cancer Outcomes ◽  
Treatment Data

Purpose Adjuvant! ( www.adjuvantonline.com ) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer–specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Results Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted − observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted − observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Conclusion Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.

scholarly journals Clinical Significance and Ultrasonographic Analysis of Color Doppler Ultrasonography in Breast Cancer

1970 ◽  
Vol 1 (2) ◽  
Author(s):  
Shangxin Yang
Keyword(s):  
Breast Cancer ◽  
Doppler Ultrasonography ◽  
Color Doppler ◽  
High Accuracy ◽  
Color Doppler Ultrasonography ◽  
Breast Cancer Patients ◽  
Accuracy Rate ◽  
Clinical Value ◽  
Object A ◽  
Treatment Data

Objective: To explore the clinical value of color Doppler ultrasonography in the diagnosis of breast cancer. Methods: 99 cases of breast cancer patients were selected as the research object, retrospective analysis of its clinical treatment data. Results: The group of 99 patients, 97 confirmed cases, 2 cases were misdiagnosed, the diagnostic accuracy rate was 97.98%. Conclusion: Color Doppler ultrasonography in patients with breast cancer has the advantages of high accuracy, simple operation and noninvasive. It is worthy of promotion.

Sign in / Sign up

Export Citation Format

Share Document